LABF.F Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €90.61 |
| 52 Week High | €90.61 |
| 52 Week Low | €52.00 |
| Beta | 0.51 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 31.80% |
| 5 Year Change | n/a |
| Change since IPO | 66.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| LABF.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -2.1% |
| 1Y | n/a | 8.5% | 29.7% |
Return vs Industry: Insufficient data to determine how LABF.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LABF.F performed against the US Market.
Price Volatility
| LABF.F volatility | |
|---|---|
| LABF.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LABF.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LABF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,137 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| LABF.F fundamental statistics | |
|---|---|
| Market cap | US$4.12b |
| Earnings (TTM) | US$165.29m |
| Revenue (TTM) | US$868.69m |
24.9x
P/E Ratio4.7x
P/S RatioIs LABF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABF.F income statement (TTM) | |
|---|---|
| Revenue | €778.00m |
| Cost of Revenue | €316.13m |
| Gross Profit | €461.87m |
| Other Expenses | €313.83m |
| Earnings | €148.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 2.89 |
| Gross Margin | 59.37% |
| Net Profit Margin | 19.03% |
| Debt/Equity Ratio | 21.5% |
How did LABF.F perform over the long term?
See historical performance and comparison